Jivi

Damoctocog alfa pegol, the active ingredient in Jivi, is a recombinant factor VIII (PEGylated) presented as a solution for injection for intravenous use. It replaces deficient clotting factor VIII in patients with hemophilia A to prevent and treat bleeding episodes. GNH USA supplies Jivi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jivi is used within the hemophilia A treatment pathway to restore clotting function. - Hemophilia A (congenital factor VIII deficiency) – prophylaxis of bleeding episodes: maintains sufficient factor VIII levels to reduce spontaneous bleeds. - Hemophilia A – on‑demand treatment of acute bleeding episodes: provides rapid factor VIII activity to stop active bleeding. - Hemophilia A during surgery – peri‑operative hemostasis: supplies factor VIII to achieve adequate clot formation during surgical procedures.

Jivi may be associated with adverse reactions following intravenous administration.

Common Side Effects: - Infusion site erythema or pain - Headache - Fever or chills - Nausea or abdominal discomfort - Fatigue or malaise

Serious or Rare Side Effects: - Development of inhibitory antibodies against factor VIII - Anaphylactic or severe hypersensitivity reactions - Thromboembolic events such as deep‑vein thrombosis - Hepatic enzyme elevations - Hemolysis or renal impairment

Prior to initiating therapy, clinicians should evaluate patient history and monitor for specific risks. - Monitor inhibitor development: perform regular factor VIII activity assays. - Assess for allergic reactions: observe patients during and after infusion. - Avoid use in patients with known hypersensitivity to PEGylated proteins. - Use caution in individuals with a history of thrombosis: evaluate risk factors. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Jivi can interact with other agents that affect coagulation or immune response.

Major Interactions (Avoid): - Concurrent use of bypassing agents (e.g., activated prothrombin complex concentrate) may increase thrombotic risk. - Co‑administration with anticoagulants (warfarin, DOACs) can reduce hemostatic efficacy. - Simultaneous infusion of other factor VIII products may provoke immune sensitisation.

Moderate Interactions (Monitor Closely): - Live vaccines may have altered immunogenicity; monitor response. - Immunosuppressive therapy could affect inhibitor formation; assess regularly. - High‑dose intravenous immunoglobulin may interfere with factor VIII activity assays.